Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | GCK | P35557 | 7/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
| ▸ | ALPI | P09923 | 1/20 | 0.34 |
| ▸ | ALPG | P10696 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PDE1A | P54750 | 1/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.33 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6858795 | 0.90 | CYP3A4 (0.34) | KMT2AMEN1POLBGCKKDM4E | |
| SCHEMBL7214537 | 0.84 | SIGMAR1 (0.43) | KMT2APOLBSIGMAR1GCKKDM4E | |
| SCHEMBL7214535 | 0.82 | KMT2A (0.36) | KMT2AMEN1POLBSIGMAR1GCK | |
| SCHEMBL7548040 | 0.79 | GCK (0.39) | SIGMAR1GCKPDE1APDE1BPDE1C | |
| SCHEMBL6330868 | 0.77 | GCK (0.32) | GCK | |
| SCHEMBL7548038 | 0.75 | KDM4C (0.41) | KMT2APOLBGCKPDE1APDE1B | |
| SCHEMBL7541012 | 0.75 | ALDH1A1 (0.39) | KMT2AGCKKDM4ELMNA | |
| SCHEMBL6325937 | 0.72 | — | — | |
| SCHEMBL7541006 | 0.72 | ALDH1A1 (0.32) | KMT2APOLBGCKKDM4ELMNA | |
| SCHEMBL6327440 | 0.68 | KDM4C (0.33) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936570-B2 | Tetrazolinone derivatives | NIHON BAYER AGROCHEM, K.K. (JP) | 2005-08-30 | — | — | US | disclosed |
| US-20040242895-A1 | Novel tetrazolinone derivatives | YANAGI AKIHIKO (JP) | 2004-12-02 | — | — | US | disclosed |
| US-6790810-B2 | Tetrazolinone derivatives | NIHON BAYER AGROCHEM K.K. (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20040102635-A1 | Novel tetrazolinone derivatives | YANAGI AKIHIKO (JP) | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102635-A1 | Novel tetrazolinone derivatives | CBR1, CBR3, CYP1B1 | KMT2A 2267/4885MEN1 3543/4885POLB 3569/4885 |
| US-20040242895-A1 | Novel tetrazolinone derivatives | CBR3, CBR1, CYP1B1 | KMT2A 2263/4885MEN1 3552/4885POLB 3582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.